Literature DB >> 12183223

Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.

Dirk Strumberg1, John L Nitiss, Jiaowang Dong, Jerrylaine Walker, Marc C Nicklaus, Kurt W Kohn, Jonathan G Heddle, Anthony Maxwell, Siegfried Seeber, Yves Pommier.   

Abstract

We report that point mutations causing alteration of the fourth alpha-helix (alpha4-helix) of the CAP homology domain of eukaryotic (Saccharomyces cerevisiae) type II topoisomerases (Ser(740)Trp, Gln(743)Pro, and Thr(744)Pro) change the selection of type II topoisomerase-mediated DNA cleavage sites promoted by Ca(2+) or produced by etoposide, the fluoroquinolone CP-115,953, or mitoxantrone. By contrast, Thr(744)Ala substitution had minimal effect on Ca(2+)- and drug-stimulated DNA cleavage sites, indicating the selectivity of single amino acid substitutions within the alpha4-helix on type II topoisomerase-mediated DNA cleavage. The equivalent mutation in the gene for Escherichia coli gyrase causing Ser(83)Trp also changed the DNA cleavage pattern generated by Ca(2+) or quinolones. Finally, Thr(744)Pro substitution in the yeast type II topoisomerase rendered the enzyme sensitive to antibacterial quinolones. This study shows that the alpha4-helix within the conserved CAP homology domain of type II topoisomerases is critical for selecting the sites of DNA cleavage. It also demonstrates that selective amino acid residues in the alpha4-helix are important in determining the activity and possibly the binding of quinolones to the topoisomerase II-DNA complexes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183223      PMCID: PMC127396          DOI: 10.1128/AAC.46.9.2735-2746.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  57 in total

1.  Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands.

Authors:  D Fass; C E Bogden; J M Berger
Journal:  Nat Struct Biol       Date:  1999-04

2.  Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Authors:  Y Pommier; G Capranico; A Orr; K W Kohn
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

Review 3.  A structural taxonomy of DNA-binding domains.

Authors:  S C Harrison
Journal:  Nature       Date:  1991-10-24       Impact factor: 49.962

4.  Evidence for a conformational change in the DNA gyrase-DNA complex from hydroxyl radical footprinting.

Authors:  G Orphanides; A Maxwell
Journal:  Nucleic Acids Res       Date:  1994-05-11       Impact factor: 16.971

5.  A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex.

Authors:  C J Willmott; A Maxwell
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

Review 6.  Drug resistance associated with altered DNA topoisomerase II.

Authors:  W T Beck; M K Danks; J S Wolverton; R Kim; M Chen
Journal:  Adv Enzyme Regul       Date:  1993

Review 7.  DNA topoisomerases: essential enzymes and lethal targets.

Authors:  A Y Chen; L F Liu
Journal:  Annu Rev Pharmacol Toxicol       Date:  1994       Impact factor: 13.820

8.  Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.

Authors:  M J Robinson; B A Martin; T D Gootz; P R McGuirk; M Moynihan; J A Sutcliffe; N Osheroff
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

9.  Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin.

Authors:  A Tanizawa; K W Kohn; Y Pommier
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

10.  A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

Authors:  S H Elsea; Y Hsiung; J L Nitiss; N Osheroff
Journal:  J Biol Chem       Date:  1995-01-27       Impact factor: 5.157

View more
  7 in total

1.  The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.

Authors:  Namiko Suda; Yasutomo Ito; Tsuneo Imai; Toyone Kikumori; Akihiko Kikuchi; Yukihiro Nishiyama; Shonen Yoshida; Motoshi Suzuki
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

2.  Assessing sensitivity to antibacterial topoisomerase II inhibitors.

Authors:  Sonia K Morgan-Linnell; Hiroshi Hiasa; Lynn Zechiedrich; John L Nitiss
Journal:  Curr Protoc Pharmacol       Date:  2007-12

3.  Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.

Authors:  Fatemeh Rafii; Miseon Park; John S Novak
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.

Authors:  Thomas Gruger; John L Nitiss; Anthony Maxwell; E Lynn Zechiedrich; Peter Heisig; Siegfried Seeber; Yves Pommier; Dirk Strumberg
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: A unifying kinetic and structural mechanism.

Authors:  Felix Mueller-Planitz; Daniel Herschlag
Journal:  J Biol Chem       Date:  2008-04-10       Impact factor: 5.486

6.  Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.

Authors:  Jissy A Kuriappan; Neil Osheroff; Marco De Vivo
Journal:  J Chem Inf Model       Date:  2019-09-09       Impact factor: 4.956

7.  DNA topoisomerase II selects DNA cleavage sites based on reactivity rather than binding affinity.

Authors:  Felix Mueller-Planitz; Daniel Herschlag
Journal:  Nucleic Acids Res       Date:  2007-05-21       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.